Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5  Years in a Long-Term, Open-Label, Phase II Study

ConclusionsBrodalumab demonstrated skin clearance and improved quality of life, with an acceptable safety profile, throughout 5  years of treatment.ClinicalTrials.gov IdentifierNCT01101100.
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research